Stephen D Gillies

List of Publications by Year
in descending order

26	1,667	361413 20	677142 22
papers	citations	h-index	g-index

26	26	26	1400
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study. Journal of Clinical Oncology, 2010, 28, 4969-4975.	1.6	220
2	A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group. Clinical Cancer Research, 2006, 12, 1750-1759.	7.0	176
3	Natural Killer Cellâ€“Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy. Blood, 1998, 91, 1706-1715.	1.4	171
4	Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients. Journal of Clinical Oncology, 2004, 22, 4463-4473.	1.6	141
5	Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model. OncoImmunology, 2019, 8, 1553477.	4.6	103
6	Enhanced Activity of Hu14.18-IL2 Immunocytokine against Murine NXS2 Neuroblastoma when Combined with Interleukin 2 Therapy. Clinical Cancer Research, 2004, 10, 4839-4847.	7.0	91
7	An anti-CD20â€“IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood, 2005, 105, 3972-3978.	1.4	83
8	A Low-Toxicity IL-2â€“Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity. Clinical Cancer Research, 2011, 17, 3673-3685.	7.0	79
9	Intratumoral hu14.18â€“IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention. Journal of Immunology, 2012, 189, 2656-2664.	0.8	64
10	Phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Cancer Immunology, Immunotherapy, 2012, 61, 2261-2271.	4.2	64
11	Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation. OncoImmunology, 2015, 4, e1014760.	4.6	49
12	Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunology, Immunotherapy, 2008, 57, 1891-1902.	4.2	47
13	Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition. , 2019, 7, 344.		45
14	Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice. Cancer Immunology, Immunotherapy, 1999, 48, 219-229.	4.2	43
15	Radiofrequency Ablation Combined with KS-IL2 Immunocytokine (EMD 273066) Results in an Enhanced Antitumor Effect against Murine Colon Adenocarcinoma. Clinical Cancer Research, 2009, 15, 4875-4884.	7.0	42
16	Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. Journal of Translational Medicine, 2009, 7, 68.	4.4	41
17	Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunology, Immunotherapy, 1996, 42, 88-92.	4.2	39
18	Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo. OncoImmunology, 2017, 6, e1323161.	4.6	39

#	Article	IF	Citations
19	Current and Potential Uses of Immunocytokines as Cancer Immunotherapy. Antibodies, 2012, 1, 149-171.	2.5	36
20	A new platform for constructing antibody-cytokine fusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity. Protein Engineering, Design and Selection, 2013, 26, 561-569.	2.1	32
21	Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models. Cancer Immunology, Immunotherapy, 2016, 65, 1003-1013.	4.2	26
22	Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model. Journal of Immunology, 2017, 198, 1575-1584.	0.8	15
23	Human and murine IL2 receptors differentially respond to the human-IL2 component of immunocytokines. OncoImmunology, 2019, 8, e1238538.	4.6	8
24	Short-course neoadjuvant in situ vaccination for murine melanoma. , 2022, 10, e003586.		7
25	Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma. , 2022, 10, e004834.		4
26	Immunocytokine augments local and abscopal response and animal survival when added to radiation and CTLA-4 checkpoint inhibition in a murine melanoma model. , 2015, 3, .		2